[177Lu]-oxodotreotide in the treatment of gastroenteropancreatic neuroendocrine tumors – Patient profile in the REAL LU study (pRospective obsErvationAL study to assess the effectiveness and outcomes associated with LUtathera)

#3850

Introduction: Somatostatin (SST) receptor (SSTR) radioligand therapy is an option for highly SSTR-expressing gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The REAL LU study [NCT04727723] is evaluating the effectiveness of [177Lu]-oxodotreotide (LuO) in unresectable/metastatic, progressive, SSTR-expressing, Grade (G)1 or G2 GEP-NETs in clinical practice.

Aim(s): This analysis aims to describe GEP-NETs patients (pts) who have been prescribed LuO.

Materials and methods: REAL LU involves 21 Italian centres. Only LuO-naïve pts ages ≥18 yrs were enrolled in the study. Treatment was as per LuO SmPC and clinical practice.

Conference:

Presenting Author:

Authors: Lastoria S, Tafuto S, Rodari M, Lania A, Sansovini M,

Keywords: REAL LU, GEP-NET, RLT, neuroendocrine tumor, radioligand therapy, [177Lu]-oxodotreotide,